Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX) and Dexcom (DXCM)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on TransMedics Group (TMDX) and Dexcom (DXCM) with bullish sentiments.
End of Quarter Sale - 50% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
TransMedics Group (TMDX)
William Blair analyst Ryan Daniels maintained a Buy rating on TransMedics Group today. The company’s shares closed last Wednesday at $100.40.
According to TipRanks.com, Daniels is a 1-star analyst with an average return of
Currently, the analyst consensus on TransMedics Group is a Moderate Buy with an average price target of $160.30, a 57.4% upside from current levels. In a report issued on March 18, TipRanks – Anthropic also upgraded the stock to Buy with a $138.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Dexcom (DXCM)
TD Cowen analyst Josh Jennings maintained a Buy rating on Dexcom today and set a price target of $84.00. The company’s shares closed last Wednesday at $62.37, close to its 52-week low of $62.34.
According to TipRanks.com, Jennings is a 3-star analyst with an average return of
Currently, the analyst consensus on Dexcom is a Strong Buy with an average price target of $86.76, representing a 38.2% upside. In a report issued on March 25, TipRanks – xAI also upgraded the stock to Buy with a $75.00 price target.
Read More on TMDX:
Disclaimer & DisclosureReport an Issue
- TransMedics: Strengthening High-Conviction Buy on Robust Growth Outlook, Next-Gen Platforms, and International Expansion Upside
- Reiterating Buy on TransMedics: Defensible OCS Leadership and Organ Management Expansion Drive Sustained Growth Outlook
- TransMedics: Early 2026 DCD and Liver Transplant Momentum Supports Upside and Maintained Buy Rating
- TransMedics price target raised to $130 from $115 at Stifel
- TransMedics Group Signals Strong Growth in Earnings Call
